Toxicology Drug Screening Market Report Scope & Overview:

The Toxicology Drug Screening Market was valued at USD 15.94 Billion in 2025 and is expected to reach USD 35.78 Billion by 2035, growing at a CAGR of 8.42% from 2026-2035.

The Toxicology Drug Screening Market will see traction due to rising pharmaceutical R&D spending, a growing drug development pipeline, and stricter safety requirements before candidates enter clinical trials. Safety assessment is shifting from animal-based tests to human-pertinent new approach methodologies, such as organ-on-a-chip models, three-dimensional cell models, and computational toxicology. Regulatory agencies in the U.S. and Europe are endorsing such techniques, while pharmaceutical companies are increasingly opting for contract research organizations to conduct their studies. Advanced technology, including automation systems, high content imaging and artificial intelligence prediction models, is playing an important role in identifying toxicity early on in the process of drug discovery. Through outsourcing to specialized labs, advanced technology is becoming available globally.

⮞In April 2025, the U.S. FDA announced a plan to reduce, refine, or potentially replace certain animal testing in monoclonal antibody development using human-relevant methods, including organ-on-chip systems. The move builds on the FDA Modernization Act 2.0, which allows non-animal alternatives to support investigational new drug applications.

U.S. Toxicology Drug Screening Market Outlook

The U.S. Toxicology Drug Screening Market was valued at USD 5.20 Billion in 2025 and is expected to reach USD 11.19 Billion by 2035, growing at a CAGR of 7.96% from 2026-2035.

The U.S. Toxicology Drug Screening Market is expanding owing to the country’s large pharmaceutical and biotechnology industry, high R&D spending, and a strong pipeline of new drug candidates requiring safety evaluation. The FDA’s regulatory framework, including the FDA Modernization Act 2.0 and the agency’s 2025 plan to reduce animal testing for monoclonal antibodies, is accelerating adoption of human-relevant testing methods. The country hosts leading suppliers and service providers such as Thermo Fisher Scientific, Agilent, Danaher, Charles River Laboratories, Labcorp, and Inotiv. Strong venture funding also supports organ-on-chip developers such as Emulate. Large biotechnology clusters further sustain strong domestic testing demand.

⮞In March 2026, Emulate showcased its AVA Emulation System and Zoë-CM2 Culture Module at the Society of Toxicology Annual Meeting in San Diego. Emulate’s Liver-Chip has demonstrated 87% sensitivity and 100% specificity in identifying hepatotoxic drugs that traditional animal models had judged safe.

By Testing Type, In Vitro Leads, While In Silico Grows Fastest

In vitro segment dominated the Toxicology Drug Screening Market in 2025, supported by growing opposition to animal testing, major advances in cell-based assays, and the cost and time advantages of laboratory testing. In vitro methods deliver toxicity information quickly and at lower cost, making them attractive to pharmaceutical companies screening large numbers of candidates. Organ-on-chip systems, 3D cell cultures, and stem cell-derived models are improving how well laboratory results predict human responses. Regulatory encouragement in the United States and Europe, together with automated instruments for high-throughput screening, continues to strengthen this segment’s leading position. Cost pressure on drug developers also favors in vitro screening.

In silico testing is the fastest-growing type, as computational models and artificial intelligence allow researchers to predict toxicity before compounds are synthesized or tested in the laboratory. Such techniques reduce development costs, save time, and make it easier to identify the safest compounds during drug development. There are software systems that can make use of large datasets containing historical data from toxicology research like the computational toxicology solution from Instem. With the rise in computing power and advancements in machine learning techniques, accuracy of models increases, and computational evidence is now being accepted by regulatory agencies as part of the integrated testing strategy.

⮞In March 2026, Insilica launched ToxIndex, an AI-powered platform designed to automate chemical safety assessments using curated datasets, computational tools, and specialized AI agents, expanding commercial options for computational toxicology and accelerating the preparation of regulatory safety reports.

By Product, Instruments Lead, While Reagents & Consumables Grow Fastest

Instruments segment dominated the Toxicology Drug Screening Market in 2025, With increased usage of analytics and screening systems in pharmaceutical, biotechnology, and contract research laboratories, there is need for core instruments in the industry. High-content imaging system, flow cytometer, plate reader, liquid chromatography-mass spectrometry systems, and liquid handlers are some of the main equipment used on a day-to-day basis. Advances being made in automation and high-throughput screening are fueling the drive for lab equipment upgrades, with major equipment suppliers Thermo Fisher Scientific, Agilent, Danaher, and Bio-Rad providing comprehensive range of instruments. Further, integration of AI-based analysis software in contemporary instruments adds more value to the equipment, enabling the segment to maintain its market leadership position. Replacement cycle is also adding to the demand dynamics.

Reagents and consumables are the fastest-growing product segment, as every screening test requires a continuous supply of assay kits, cell culture media, antibodies, biomarkers, and specialized reagents. The growing number of in vitro tests performed worldwide is driving steady recurring demand. Organ-on-chip and 3D cell culture systems use specialized chips, matrices, and media that must be replaced for each study, adding further consumable spending. The development of new biomarkers for liver, cardiac, and kidney toxicity is creating demand for advanced reagent kits. Rising research activity in emerging economies is also expected to sustain strong segment growth. Recurring purchases improve supplier revenue visibility.

⮞In April 2025, Biologix Group Limited introduced a laboratory consumables portfolio covering cell-culture buffers, microbiological media, culture flasks, media bottles, and filtration products, expanding the range of routine laboratory supplies available to researchers conducting cell-based experiments and laboratory testing.

By Application, Immunotoxicity Leads, While DART Grows Fastest

Immunotoxicity segment dominated the Toxicology Drug Screening Market in 2025, The increasing importance of the interaction of drugs under development with the immune system cannot be doubted. Due to the growing presence of biologic drugs, monoclonal antibodies, cell therapy, and immunotherapy, there arises an urgent need for the immune safety evaluation, as these drugs can cause cytokine release, hypersensitivity, or immunosuppression. Regulatory guidelines require immunotoxicity evaluation for many new drug classes. Advances in in vitro immune assays and human-relevant models are improving prediction of immune-related adverse events. The large and growing biologics pipeline is expected to keep immunotoxicity testing the largest application segment. New cell therapies add further testing requirements.

DART is the fastest-growing application, driven by stricter regulatory requirements for evaluating effects on fertility, pregnancy, and fetal development. Regulators require DART studies for most new drugs, particularly those intended for women of childbearing age. Growing attention to women’s health and pediatric medicines is increasing demand for these studies. DART testing has traditionally relied on animal models, but new in vitro approaches such as embryonic stem cell tests and zebrafish models are gaining acceptance. These methods can reduce cost and animal use, supporting rapid growth of DART screening throughout the forecast period. Regulatory guidance continues to evolve in this area.

⮞In January 2026, the Netherlands' National Institute for Public Health and the Environment highlighted research combining zebrafish embryos and Caenorhabditis elegans to screen chemicals for developmental and reproductive toxicity, reporting that the combined models identified 75% of known reproductive toxicants and supported their complementary use in hazard screening.

Regional Analysis

North America Toxicology Drug Screening Market Insights

North America accounted for approximately 41.28% of the Toxicology Drug Screening Market in 2025, the largest share among all regions, driven by advanced research infrastructure, high pharmaceutical R&D investment, and the presence of major drug developers. The United States generates most regional revenue, supported by stringent FDA safety requirements and a large network of contract research organizations and testing laboratories. Leading companies including Thermo Fisher Scientific, Agilent, Danaher, Charles River Laboratories, Labcorp, and Inotiv are headquartered in the region. Regulatory support for non-animal methods is further accelerating adoption of organ-on-chip and in silico toxicology tools. Strong academic research further supports innovation.

Canada has emerged as the fastest growing country in the region, owing to investments made by the government towards pharmaceuticals research, growth in the biotech industry and university and industry collaboration. Advanced technologies used in toxicology testing are increasingly being embraced by research institutions in Canada. Mexico has become an important emerging country due to pharmaceutical manufacturing and clinical research being performed there. Venturing funds and increasing CRO services have been driving factors towards expansion in the market in the whole region. However, the high price of such testing technologies, and the need for validation before gaining acceptance by the regulatory bodies may hamper adoption, especially on the side of smaller biotechs.

⮞In April 2025, Roche announced plans to invest USD 50 billion in its U.S. pharmaceutical and diagnostics operations over five years, including new and expanded research and development sites and manufacturing facilities, strengthening the broader pharmaceutical research ecosystem that supports demand for preclinical drug safety assessment.

Europe Toxicology Drug Screening Market Insights

Europe continues to be the second-largest regional market, supported by Germany, the United Kingdom, France, Italy, and Spain, which have strong pharmaceutical industries and advanced research infrastructure. The region has long led efforts to reduce animal testing, including the EU ban on animal testing for cosmetics and support for alternative methods through the European Union Reference Laboratory for alternatives to animal testing. The REACH chemicals regulation also drives demand for toxicology data. Major service providers, including Eurofins Scientific and Merck KGaA, operate extensive testing networks across Europe, supporting steady regional demand. Chemical safety testing adds further testing volume beyond pharmaceuticals.

Germany is the largest market in Europe due to the strong presence of pharmaceutical and chemical industries and advanced technological skills. The United Kingdom is the fastest growing country in the region due to governmental support of the life science industry, strong biotechnology industry, and developments of new technologies such as organ-on-chip systems provided by companies such as CN Bio. France, Italy, and Spain also provide contributions via established pharmaceutical companies and institutes. The Netherlands is home to the leading company in organ-on-chip technology MIMETAS. However, the way to the implementation is complicated by a complicated procedure of approval and the uneven acceptance of innovative methods across countries. In the long run, this process will be unified.

⮞In July 2026, Italian discovery-services company Axxam and BiomimX announced a collaboration combining early drug-discovery capabilities with uBeat organ-on-chip technology, integrating living human cells, microfluidics, and physical stimuli to advance human-relevant in vitro models for preclinical drug research.

Asia-Pacific Toxicology Drug Screening Market Insights

The Asia-Pacific region is presently experiencing the highest growth in the Toxicology Drug Screening Market with a projected CAGR of about 10.36% during 2026 to 2035. This growth is attributed to high R&D activities, the growth of the pharmaceutical industry, and high investments in the healthcare sector. China leads as the largest market in the region due to the fast growth of the pharmaceutical industry in China, increasing R&D spending, and presence of leading contract research organizations such as WuXi AppTec. The encouragement of biotechnology innovations and regulatory reforms that are aligned to international standards are also increasing the demand for toxicology testing services. The local manufacturers are investing in safety testing facilities.

India is the fastest-growing country in the region due to the strong generics and biosimilars markets, increasing contract research activities, and support by the government for pharmaceutical innovation. The contract research organizations in India provide cost-efficient preclinical testing services for global pharmaceutical companies. Japan is still an important market for the segment due to the developed pharmaceutical industry and strict drug safety regulations in the country. South Korea and Australia also play a role in the growth of the market through their developed biotechnology industries and clinical research activities. In vitro and in silico testing techniques and high outsourcing from Western companies are expected to boost the regional growth during the forecast period.

⮞In July 2026, VivoSim Labs announced its first commercial sales in mainland China for NAMkind toxicology and efficacy testing services, securing initial engagements with a Shanghai-based oncology biotechnology company and a Chengdu-based pharmaceutical company for human-tissue-model-based gastrointestinal toxicology screening and efficacy profiling.

MEA & Latin America Toxicology Drug Screening Market Insights

The Middle East & Africa region represents a smaller but growing share of the Toxicology Drug Screening Market, with GCC countries forming the largest regional market and South Africa showing the fastest growth. Gulf states such as Saudi Arabia and the UAE are investing in healthcare infrastructure, biotechnology research, and local pharmaceutical manufacturing as part of economic diversification strategies. These investments are increasing demand for drug safety testing capabilities. South Africa benefits from established research institutions and clinical trial activity. However, limited specialized testing infrastructure and reliance on imported equipment restrict faster regional growth. Training programs may gradually improve local capability.

The future for Latin America is bright, with the region experiencing continuous growth, with Brazil being the fastest-growing and largest market in Latin America. The growth is driven by the development of the country’s pharmaceutical industry and increasing research and contract research organizations. Argentina and Mexico are contributing with pharmaceutical production and clinical research services. Regulatory bodies in the region, including Brazil’s ANVISA, are increasing standards of drug safety, driving more interest in toxicology testing. However, there are still economic instability, a lack of research funding, and dependence on imported instruments and reagents that restrict fast growth in the region.

In April 2026, the Emirates Drug Establishment announced the UAE's first fully AI-discovered and developed drug candidate, ISM0387, created by Insilico Medicine. The milestone illustrates the expansion of computational drug discovery in the Gulf, with advancing candidates potentially requiring downstream preclinical safety evaluation.

Market Dynamics

Growth Drivers: Rising R&D Investment and New Approach Methodologies

Growth in the Toxicology Drug Screening Market is primarily attributed to rising pharmaceutical and biotechnology R&D investment and a growing pipeline of drug candidates requiring safety evaluation. The increasing prevalence of chronic diseases, including cancer, cardiovascular disease, and diabetes, is driving demand for new therapies. According to Cancer Research UK, new cancer cases are projected to reach about 27.5 million worldwide by 2040. Drug developers are placing greater emphasis on early safety assessment, since identifying toxicity before clinical trials can save significant development costs and reduce late-stage failures that waste years of research investment. Each avoided failure saves substantial development spending.

The rapid adoption of new approach methodologies is further reinforcing market growth. Organ-on-chip systems, 3D cell cultures, stem cell-derived models, and computational toxicology tools provide more human-relevant predictions than traditional animal studies. Regulatory support is accelerating this shift, including the FDA Modernization Act 2.0 and the FDA’s 2025 plan to reduce animal testing for monoclonal antibodies. Studies showing that human Liver-Chips can identify hepatotoxic drugs missed by animal models are building confidence among drug developers. The growing outsourcing of safety testing to contract research organizations is also expanding access to advanced screening technologies. Shared platforms also lower entry costs for smaller firms.

⮞In May 2026, South Korea's Celltrion initiated primate toxicology studies for its investigational obesity candidate CT-G32, advancing the program toward a planned investigational new drug application in the first half of 2027 and illustrating continuing demand for preclinical safety assessment as pharmaceutical pipelines advance.

Restraints: Long Testing Timelines and Regulatory Complexity

The lengthy testing process is still acting as a bottleneck for the growth of the market. The comprehensive toxicology programs that include in vivo studies for chronic toxicity, carcinogenicity and developmental toxicity can take from a few months to a few years, adding a lot of expenses for drug development and can delay the entry of a drug into clinical trials. Though in vitro and in silico tests can help in reducing some phases, but they still need to be validated by existing data to be accepted by regulators as an alternative method. Shortage of laboratory animals and study directors has made it difficult for contract research organizations to perform preclinical studies and initiate clinical trials.

Another constraint is regulatory complexity where the drug developers need to go through different toxicology processes depending on the region they are developing drugs for like the United States, Europe, Japan, China and others. Though the International Council for Harmonisation provides international guidelines that have some common standards, there are still differences in regional toxicology requirements. Adoption of new approach methodologies by regulators is still in process and it adds uncertainty for the companies that want to invest in alternatives to animal testing. The high price of advanced instruments, organ-on-chip systems and software can be a barrier for small biotech companies and academic laboratories.

Opportunities: Organ-on-Chip Platforms and AI-Driven Toxicology

The development of organ-on-chip and microphysiological systems creates a significant opportunity for the market, as these platforms recreate human organ functions and improve the prediction of drug toxicity. Companies such as Emulate, CN Bio, MIMETAS, and InSphero are working with pharmaceutical companies and regulators to validate their technologies. Multi-organ systems that connect liver, heart, kidney, and other tissues can model complex drug interactions. Growing venture funding, including CN Bio’s Series B financing, is supporting commercialization. Suppliers that combine validated platforms, consumables, and analysis software can capture recurring revenue as adoption expands across drug development. Regulatory validation remains the key milestone.

At the same time, artificial intelligence and computational toxicology provide a major growth opportunity. Machine learning models trained on large toxicology databases can predict safety risks before compounds are synthesized, reducing costs and animal use. Companies such as Instem, Certara, and Simulations Plus offer software that supports regulatory-accepted predictions. Integrating AI with in vitro data and organ-on-chip results can create more powerful predictive platforms. Expanding pharmaceutical R&D and contract research activity in Asia-Pacific, Latin America, and the Middle East also creates demand for affordable, efficient testing solutions in emerging markets. Local partnerships can accelerate entry into several of these fast-growing regions.

⮞In April 2026, InSphero launched its 3D InSight DIGIT platform, combining patient-derived human intestinal organoids with scalable Gri3D technology and automated imaging to support high-throughput assessment of drug-induced gastrointestinal toxicity during early drug discovery.

Toxicology Drug Screening Market Key Players

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• Merck KGaA

• Charles River Laboratories International, Inc.

• Eurofins Scientific SE

• Danaher Corporation

• Labcorp Holdings Inc.

• Promega Corporation

• Thermo Fisher Scientific Inc.

• WuXi AppTec Co., Ltd.

• Inotiv, Inc.

• Instem plc

• Emulate, Inc.

• CN Bio Innovations Ltd.

• MIMETAS B.V.

• InSphero AG

• Certara, Inc.

• Simulations Plus, Inc.

• SGS SA

Toxicology Drug Screening Market Report Scope: